Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin

被引:32
作者
Nam, So Hee [1 ]
Xu, Ying Ji [1 ]
Nam, Hyemi [1 ]
Jin, Geun-woo [1 ]
Jeong, Yunseong [1 ]
An, Songhie [1 ]
Park, Jong-Sang [1 ]
机构
[1] Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151747, South Korea
关键词
Risedronate; Bisphosphonate; Ion pairs; Transdermal delivery; INVITRO PERCUTANEOUS-ABSORPTION; DRUG-DELIVERY; PENETRATION ENHANCERS; DERMAL DELIVERY; COUNTER-IONS; IN-VITRO; OSTEONECROSIS; JAWS; BISPHOSPHONATES; PERMEABILITY;
D O I
10.1016/j.ijpharm.2011.07.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ion-paired solutions of risedronate (RIS) with L-arginine (ARG), L-lysine (LYS), and diethylenetriamine (DETA) were tested in vitro for their potential to enhance the penetration of RIS across the skin of hairless mouse. The xylene solubilities of RIS paired with ARG, LYS, and DETA in molar ratios of 1:2, 1:2, and 1:1 were 8.9%, 12.0%, and 2.1%, respectively, in comparison with the solubility in deionized water, but non-ion-paired RIS was not detected in xylene. In vitro permeation tests were performed on the skin of hairless mice, and the results indicated that ion-paired RIS could penetrate mice skin about 36 times more effectively than RIS alone. The cumulative amount of ion paired RIS after 24h resulted in 475.18 +/- 94.19 mu g/cm(2) and 511.21 +/- 106.52 mu g/cm(2) at molar ratio of 1:2 and 1:1. The cumulative amount of RIS alone was as low as 14.13 +/- 5.49 mu g/cm(2) in 24 h. The hairless mice showed no skin irritation after a single administration of RIS alone and ion-paired RIS (1:2 molar ratio with ARG, and 1:1 molar ratio with DETA). In this study, we found that RIS can be delivered transdermally, and the ion-paired system in an aqueous solution showed an enhanced flux through the skin barrier. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 41 条
  • [1] Adverse Effects of Bisphosphonates
    Abrahamsen, Bo
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2010, 86 (06) : 421 - 435
  • [2] Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies
    Assael, Leon A.
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 35 - 43
  • [3] WATER SOLUBILITY AND OCTANOL-WATER PARTITION-COEFFICIENTS OF ORGANICS - LIMITATIONS OF THE SOLUBILITY-PARTITION COEFFICIENT CORRELATION
    BANERJEE, S
    YALKOWSKY, SH
    VALVANI, SC
    [J]. ENVIRONMENTAL SCIENCE & TECHNOLOGY, 1980, 14 (10) : 1227 - 1229
  • [4] BARRY B W, 1987, Journal of Controlled Release, V6, P85, DOI 10.1016/0168-3659(87)90066-6
  • [5] Novel mechanisms and devices to enable successful transdermal drug delivery
    Barry, BW
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (02) : 101 - 114
  • [6] Drug delivery routes in skin: a novel approach
    Barry, BW
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 : S31 - S40
  • [7] The hairless mouse in skin research
    Benavides, Fernando
    Oberyszyn, Tatiana M.
    VanBuskirk, Anne M.
    Reeve, Vivienne E.
    Kusewitt, Donna F.
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2009, 53 (01) : 10 - 18
  • [8] Adverse cutaneous drug reaction to alendronate
    Brinkmeier, Thomas
    Kuegler, Katrin
    Lepoittevin, Jean-Pierre
    Frosch, Peter J.
    [J]. CONTACT DERMATITIS, 2007, 57 (02) : 123 - U5
  • [9] METHODS FOR INVITRO PERCUTANEOUS-ABSORPTION STUDIES .2. ANIMAL-MODELS FOR HUMAN-SKIN
    BRONAUGH, RL
    STEWART, RF
    CONGDON, ER
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1982, 62 (03) : 481 - 488
  • [10] Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases
    Brooks, John K.
    Gilson, Allen J.
    Sindler, Arnold J.
    Ashman, Steven G.
    Schwartz, Kevin G.
    Nikitakis, Nikolaos G.
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2007, 103 (06): : 780 - 786